INT17848
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
The potential for similar interactions with cyclooxygenase-2-specific inhibitors has not been fully explored. | |||||||||||||||
| |||||||||||||||
|
In addition, molecular modeling and docking of the tested compounds into cyclooxygenase II complexed with its bound inhibitor indomethacin (4COX) using molsoft icm 3.4-8C program was performed in order to predict the affinity and orientation of the synthesized compounds at the active site. | |||||||||||||||
| |||||||||||||||
|
The other two structures namely PGFS and PGIS were added to make the dataset of 7649 structures in which four of them were known to bind PGH2. | |||||||||||||||
| |||||||||||||||
|
These latter conclusions are based on the findings that the nonsteroidal anti-inflammatory drug diclofenac binds a single monomer of native huPGHS-2, having an unmodified Ser530 to inhibit the enzyme, and that diclofenac inhibits PGH(2) but not 15-hydroperoxyeicosatraenoic acid formation by acetylated huPGHS-2. | |||||||||||||||
| |||||||||||||||
|
Although the substrate PGH2, the ligand and its interactions with the protein were not taken into account during any of the computational steps performed by MultiBind, it never-the-less detected the key residues thought to be involved in the catalytic mechanism and superimposed the ligand molecules to similar locations in space, supporting the correctness of the alignment. | |||||||||||||||
| |||||||||||||||
|
distance from the bound PGH2 and Ligand, it was found that common amino acid residues participated in the binding of PGH2 to the synthases in the docked model and the ligand in the crystal structure obtained from PDB Among the common residues, the cofactors GSH, NADP and HEME involved in the catalytic mechanism of the synthases PGDS (GSH) [12], PGFS (NADP) [14] and PGIS (HEME) [15] respectively are also shown in Figure 1.
| |||||||||||||||
| |||||||||||||||
|
Convergence seems to be limited to similarity in the ability to bind PGH2 specifically and may not extend to the precise way in which this is achieved as indicated by the lack of similarity which can be characterized as a PGH2 binding site. | |||||||||||||||
| |||||||||||||||
|
Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids. | |||||||||||||||
| |||||||||||||||
|
Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. | |||||||||||||||
| |||||||||||||||
|
Cyclooxygenase 2 (COX-2) has been suggested to be associated with liver carcinogenesis. | |||||||||||||||
| |||||||||||||||
|
While preliminary evidence has supported novel roles for these drugs in ankylosing spondylitis and in cancer prevention, accumulating evidence shows that some cyclooxygenase-2 and perhaps all nonsteroidal anti-inflammatory drugs are associated with cardiovascular toxicity. | |||||||||||||||
| |||||||||||||||
|
BACKGROUND: Lumiracoxib (Prexige; Novartis Pharma AG, Basel, Switzerland) is a cyclooxygenase-2 selective inhibitor associated with improved gastrointestinal safety compared with nonsteroidal anti-inflammatory drugs, in patients with osteoarthritis. | |||||||||||||||
| |||||||||||||||
|
To summarize the evidence from published observational studies on the risk of myocardial infarction associated with both traditional NSAIDs (tNSAIDs) and selective inhibitors of cyclooxygenase-2 (Coxibs), the authors conducted a systematic review of cohort and case-control studies on NSAIDs and myocardial infarction published between 2000 and 2005. | |||||||||||||||
| |||||||||||||||
|
However, less is known about how the risk of hypertension is associated with cyclooxygenase 2 selective inhibitors (coxibs), especially celecoxib, the only coxib remaining on the market. | |||||||||||||||
| |||||||||||||||
|
arachidonic acid by the catalytic activities of the cyclooxygenase-2 (Cox-2) | |||||||||||||||
| |||||||||||||||
|
BACKGROUND: Licofelone, a potent antiinflammatory agent has been reported to interfere with the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) signaling pathways with few side-effects. | |||||||||||||||
| |||||||||||||||
|
Recent concerns regarding potential cardiovascular toxicities associated with cox-2 selective inhibitors may favor non-selective NSAID/PPI co-therapy as the preferred choice. | |||||||||||||||
| |||||||||||||||
|
Molecular modelling of the differential interaction between several non-steroidal anti-inflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2). | |||||||||||||||
| |||||||||||||||
|
Our results indicate no strong association between the four most frequent PTGS2 SNPs and the risk of breast cancer.
| |||||||||||||||
| |||||||||||||||
|
Taken together, the results appear to indicate no association between PTGS2 SNPs (in their most frequent haplotypes) and the risk of breast cancer.
| |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.